JPH0324480B2 - - Google Patents

Info

Publication number
JPH0324480B2
JPH0324480B2 JP59248259A JP24825984A JPH0324480B2 JP H0324480 B2 JPH0324480 B2 JP H0324480B2 JP 59248259 A JP59248259 A JP 59248259A JP 24825984 A JP24825984 A JP 24825984A JP H0324480 B2 JPH0324480 B2 JP H0324480B2
Authority
JP
Japan
Prior art keywords
digitalis
producing
antibody
fab
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP59248259A
Other languages
English (en)
Japanese (ja)
Other versions
JPS60132922A (ja
Inventor
Batsutsu Hansuugeoruku
Yungufuaa Heruberuto
Rentsu Herumuuto
Reedaa Aruberuto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Publication of JPS60132922A publication Critical patent/JPS60132922A/ja
Publication of JPH0324480B2 publication Critical patent/JPH0324480B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP59248259A 1983-11-26 1984-11-26 ジギタリス抗体の製造法 Granted JPS60132922A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19833342870 DE3342870A1 (de) 1983-11-26 1983-11-26 Digitalis-antikoerper, verfahren zu ihrer herstellung und ihre verwendung zur therapie von digitalis-intoxikationen
DE3342870.0 1983-11-26

Publications (2)

Publication Number Publication Date
JPS60132922A JPS60132922A (ja) 1985-07-16
JPH0324480B2 true JPH0324480B2 (enExample) 1991-04-03

Family

ID=6215371

Family Applications (1)

Application Number Title Priority Date Filing Date
JP59248259A Granted JPS60132922A (ja) 1983-11-26 1984-11-26 ジギタリス抗体の製造法

Country Status (8)

Country Link
US (1) US4742159A (enExample)
EP (1) EP0143413B1 (enExample)
JP (1) JPS60132922A (enExample)
AT (1) ATE64141T1 (enExample)
CA (1) CA1242393A (enExample)
DE (2) DE3342870A1 (enExample)
ES (1) ES537909A0 (enExample)
SU (1) SU1455999A3 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849352A (en) 1984-10-09 1989-07-18 Sullivan John B Antibody purification process
US4841024A (en) * 1986-09-15 1989-06-20 Becton Dickinson And Company Purification of antibodies
US4814433A (en) * 1987-09-16 1989-03-21 Miles Inc. Method for obtaining a papain-free antibody fragment preparation
JPH0623761B2 (ja) * 1988-12-09 1994-03-30 株式会社ピーシーシーテクノロジー 配糖化した化合物を生産する細胞の検出方法
US5328834A (en) * 1989-09-08 1994-07-12 Unisyn Technologies, Inc. Method for preparing immunoglobulin fragments
ES2138662T3 (es) 1993-06-03 2000-01-16 Therapeutic Antibodies Inc Produccion de fragmentos de anticuerpos.
US7348294B2 (en) * 2000-05-25 2008-03-25 Kaneka Corporation Adsorbent and method for adsorbing cardiac glycoside
FR2810667B1 (fr) * 2000-06-23 2004-09-03 Warner Lambert Co Procede d'isolement et de purification d'une proteine, et proteine obtenue
US6802966B2 (en) * 2001-08-14 2004-10-12 W. R. Grace & Co. Conn. Solid compositions for selective adsorption from complex mixtures
US6987079B2 (en) * 2001-08-14 2006-01-17 W.R. Grace & Co.-Conn. Supported catalyst systems
US7794716B2 (en) 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
JP5385135B2 (ja) 2006-07-03 2014-01-08 チャールズ デイビッド アデア， 細胞接着分子の発現を調節するための組成物
CA2745111A1 (en) 2008-12-03 2010-06-10 Research Development Foundation Modulation of olfml-3 mediated angiogenesis
US8663637B2 (en) 2011-08-05 2014-03-04 Research Development Foundation Methods and compositions for modulation of Olfml3 mediated angiogenesis
EP2912064B1 (en) 2012-10-24 2019-04-24 Research Development Foundation Jam-c antibodies and methods for treatment of cancer
CN114621346B (zh) 2013-08-21 2025-06-10 德克萨斯州大学系统董事会 用于靶向连接蛋白半通道的组合物和方法
JP7090545B2 (ja) 2015-12-02 2022-06-24 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子並びにそれらの治療的使用
WO2017096017A1 (en) 2015-12-02 2017-06-08 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
WO2017147561A1 (en) 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System CONNEXIN (Cx) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF
EP3436481B1 (en) 2016-03-29 2021-06-30 Stcube, Inc. Dual function antibodies specific to glycosylated pd-l1 and methods of use thereof
CN109195990A (zh) 2016-03-30 2019-01-11 Musc研究发展基金会 通过靶向糖蛋白a重复优势蛋白(garp)治疗和诊断癌症以及单独或联合提供有效免疫疗法的方法
WO2018017673A1 (en) 2016-07-20 2018-01-25 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1
EP3630834A1 (en) 2017-05-31 2020-04-08 STCube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
JP7369038B2 (ja) 2017-05-31 2023-10-25 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子並びにその治療的使用
WO2018226671A1 (en) 2017-06-06 2018-12-13 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
DE112018005145T5 (de) 2017-09-15 2020-07-23 The Regents Of The University Of California Hemmung von aminoacylase 3 (aa3) bei der behandlung von krebs
AU2018341454B2 (en) 2017-09-26 2023-09-28 The Regents Of The University Of California Compositions and methods for treating cancer
EP3802616A4 (en) 2018-06-04 2022-03-30 University of Maryland, Baltimore PROCEDURES FOR THE PREVENTION OF AN ACUTE KIDNEY LESION
EP4041767A1 (en) 2019-09-26 2022-08-17 StCube & Co. Antibodies specific to glycosylated ctla-4 and methods of use thereof
CN114829404B (zh) 2019-10-09 2025-09-09 斯特库比公司 对糖基化的lag3特异的抗体及其使用方法
CA3168337A1 (en) 2020-02-17 2021-08-26 Marie-Andree Forget Methods for expansion of tumor infiltrating lymphocytes and use thereof
CN113736744B (zh) * 2021-10-14 2023-07-18 江南大学 洋地黄毒苷单克隆抗体杂交瘤细胞株及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3790475A (en) * 1972-03-27 1974-02-05 Corning Glass Works Porous glass support material
US4039652A (en) * 1973-10-11 1977-08-02 Miles Laboratories, Inc. Column method of immunoassay employing an immobilized binding partner
US4081246A (en) * 1976-05-03 1978-03-28 Beckman Instruments, Inc. Solid phase column immunoassay procedure employing novel immunochemical composites
US4081245A (en) * 1976-05-03 1978-03-28 Beckman Instruments, Inc. Immunoassay procedure employing novel immunochemical composites
US4232004A (en) * 1977-09-21 1980-11-04 American National Red Cross Antibody-specific solid phase immunoadsorbent, preparation thereof, and antibody purification therewith
US4434234A (en) * 1981-04-02 1984-02-28 The Upjohn Company Method and kit for silver staining substances supported in matrix

Also Published As

Publication number Publication date
JPS60132922A (ja) 1985-07-16
ES8600770A1 (es) 1985-11-01
ATE64141T1 (de) 1991-06-15
DE3484673D1 (de) 1991-07-11
CA1242393A (en) 1988-09-27
EP0143413B1 (de) 1991-06-05
SU1455999A3 (ru) 1989-01-30
EP0143413A3 (en) 1988-07-20
EP0143413A2 (de) 1985-06-05
DE3342870A1 (de) 1985-06-05
ES537909A0 (es) 1985-11-01
US4742159A (en) 1988-05-03

Similar Documents

Publication Publication Date Title
JPH0324480B2 (enExample)
US4361509A (en) Ultrapurification of factor VIII using monoclonal antibodies
JP2002539081A (ja) 血液と血漿およびその他の液体に含まれるプリオンの除去
KR102079487B1 (ko) Ｉｇａ를 농축시키는 방법
JPH08511015A (ja) 治療用抗体断片
JPH06107561A (ja) 静脈内相容性免疫グロブリン− ｇ− 製剤の製造方法
US4302385A (en) Placenta-specific tissue protein PP10
US20030190732A1 (en) Plasma fraction containing bikunin, method for the production thereof and use of the same
US4746731A (en) Isolated tissue protein PP18
JPH09506256A (ja) メンブレンクロマトグラフィーによるビタミンｋ依存性蛋白の精製
US4232004A (en) Antibody-specific solid phase immunoadsorbent, preparation thereof, and antibody purification therewith
JPH0132839B2 (enExample)
Aalberse et al. The purification of human polyclonal IgE by immunosorption
US4594328A (en) Tissue protein PP21, a process for obtaining it and its use
JPH09504532A (ja) クロマトグラフィー法による第８因子を含むウィルス不活性化分画の製造方法
US20090281282A1 (en) Method for the isolation of haptoglobin
RU2325171C1 (ru) Способ выделения и очистки трофобластического бета-1-гликопротеина
KR100245542B1 (ko) 응고 인자 xiii 또는 xiiia의 정제방법 및 인자 xiiia에 대한 모노클로날 항체
Biewenga et al. Binding of human IgA myeloma proteins to protein A. Evidence for different binding mechanisms
JP4777599B2 (ja) ヒト抗胸腺細胞免疫グロブリンの製造方法
JP2001509170A (ja) フォンビルブラント因子含有出発物質からのフォンビルブラント因子のクロマトグラフィー精製法または分画法
EP0539584B1 (en) Reagent for diagnosing mycoplasma pneumoniae
JP2519561B2 (ja) 酸性糖タンパク質
JPS62258399A (ja) Ｃ−反応性蛋白質の精製方法
JPH07121876B2 (ja) 静注用免疫グロブリンの製法

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term